STORY: Eli Lilly said Monday it will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying ...

By Purvi Agarwal and Sanchayaita Roy (Reuters) -European shares climbed on Monday, recouping some of last week's losses as ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Nvidia (NVDA, Financials) said Tuesday it is partnering with Novo Nordisk to accelerate drug discovery using its generative ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

But too few firms think deeply about what they want their culture to be, or about how to embed it. As the latest episode of ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...